AbbVie Inc (ABBV)vsWest Pharmaceutical Services Inc (WST)
ABBV
AbbVie Inc
$291.27
+1.07%
HEALTHCARE · Cap: $521.11B
WST
West Pharmaceutical Services Inc
$399.81
+1.87%
HEALTHCARE · Cap: $28.03B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 1884% more annual revenue ($66.01B vs $3.33B). WST leads profitability with a 17.0% profit margin vs 15.7%. ABBV appears more attractively valued with a PEG of 0.60. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
WST
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.27
$133.98 premium
Margin of Safety
-43.3%
Fair Value
$171.84
Current Price
$399.81
$227.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Conservative balance sheet, low leverage
Strong operational efficiency at 22.5%
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 9.4x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Return on Equity, Debt/Equity. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : WST
The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 51.0x leaves little room for execution misses.
Key Dynamics to Monitor
WST carries more volatility with a beta of 1.13 — expect wider price swings.
WST is growing revenue faster at 13.8% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (77/100 vs 56/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?